Cencora, Inc. (NYSE: COR) Stock Competitors & Peer Comparison

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, MCK has a market cap of 103.2B. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while MCK trades at $881.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas MCK's P/E ratio is 21.59. In terms of profitability, COR's ROE is +1.06%, compared to MCK's ROE of -1.94%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, CAH has a market cap of 54.9B. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while CAH trades at $234.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas CAH's P/E ratio is 22.49. In terms of profitability, COR's ROE is +1.06%, compared to CAH's ROE of -0.60%. Regarding short-term risk, COR is less volatile compared to CAH. This indicates lower risk in terms of short-term price fluctuations for COR.Check CAH's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.06%, compared to ABC's ROE of +1.06%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, HSIC has a market cap of 10.1B. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while HSIC trades at $88.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas HSIC's P/E ratio is 16.64. In terms of profitability, COR's ROE is +1.06%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for COR.Check HSIC's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.06%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, AHG has a market cap of 678.6M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while AHG trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas AHG's P/E ratio is -3.72. In terms of profitability, COR's ROE is +1.06%, compared to AHG's ROE of -0.50%. Regarding short-term risk, COR is less volatile compared to AHG. This indicates lower risk in terms of short-term price fluctuations for COR.Check AHG's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while OMI trades at $2.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.06%, compared to OMI's ROE of +0.63%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while EMPG trades at $17.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas EMPG's P/E ratio is 192.89. In terms of profitability, COR's ROE is +1.06%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, COR is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for COR.Check EMPG's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, ACH has a market cap of 82.7M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while ACH trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas ACH's P/E ratio is 1.59. In terms of profitability, COR's ROE is +1.06%, compared to ACH's ROE of +0.63%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.06%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates lower risk in terms of short-term price fluctuations for COR.Check HX's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, YI has a market cap of 31.1M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while YI trades at $3.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas YI's P/E ratio is -2.54. In terms of profitability, COR's ROE is +1.06%, compared to YI's ROE of +0.14%. Regarding short-term risk, COR is less volatile compared to YI. This indicates lower risk in terms of short-term price fluctuations for COR.Check YI's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while WGRX trades at $3.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas WGRX's P/E ratio is -0.33. In terms of profitability, COR's ROE is +1.06%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while ZYXI trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.06%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, MEDS has a market cap of 2.4M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while MEDS trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas MEDS's P/E ratio is N/A. In terms of profitability, COR's ROE is +1.06%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, COR is less volatile compared to MEDS. This indicates lower risk in terms of short-term price fluctuations for COR.Check MEDS's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, HKPD has a market cap of 1.3M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while HKPD trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas HKPD's P/E ratio is -2.04. In terms of profitability, COR's ROE is +1.06%, compared to HKPD's ROE of -0.15%. Regarding short-term risk, COR is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for COR.Check HKPD's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, SNYR has a market cap of 1.1M. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while SNYR trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas SNYR's P/E ratio is -0.07. In terms of profitability, COR's ROE is +1.06%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, RDGT has a market cap of 745.1K. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while RDGT trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas RDGT's P/E ratio is -0.02. In terms of profitability, COR's ROE is +1.06%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here

Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, COR stands at 62.6B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $321.57 on the NYSE, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

COR currently has a P/E ratio of 18.75, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.06%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here